An evaluation of recombinant leukocyte a interferon with aspirin in patients with metastatic renal cell cancer

Edward T. Creagan; Jan C. Buckner; Richard G. Hahn; Ronald R. Richardson; Daniel J. Schaid; John S. Kovach

doi:10.1002/1097-0142(19880501)61:9<1787::AID-CNCR2820610911>3.0.CO;2-Q

An evaluation of recombinant leukocyte a interferon with aspirin in patients with metastatic renal cell cancer

Edward T. Creagan, Jan C. Buckner, Richard G. Hahn, Ronald R. Richardson, Daniel J. Schaid, John S. Kovach

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

The authors designed a clinical trial to assess the impact of aspirin (ASA) (600 mg four times daily) on the constitutional sequelae of recombinant leakocyte A interferon (IFN‐α2A), 20 × 10⁶ U/m² thrice weekly, in 29 patients with advanced renal cell cancer (RCC). Aspirin provided no meaningful amelioration of side effects compared to our prior experience of IFN‐α2A alone. Interestingly, the objective response rate of 34% (10/29) was considerably higher than the 15% recently reported from an aggregate of 344 patients participating in 14 prospective clinical trials. In light of small numbers, subtle selection biases, and the well‐recognized hazards of retrospective analyses, currently it is unclear if the apparent therapeutic advantage from ASA plus IFN‐α2A reflects chance occurrence or therapeutic potentiation from ASA. A randomized trial is planned to determine if ASA may have enhanced the efficacy of IFN‐α2A in patients with advanced RCC.

Original language	English (US)
Pages (from-to)	1787-1791
Number of pages	5
Journal	Cancer
Volume	61
Issue number	9
DOIs	https://doi.org/10.1002/1097-0142(19880501)61:9<1787::AID-CNCR2820610911>3.0.CO;2-Q
State	Published - May 1 1988

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(19880501)61:9<1787::AID-CNCR2820610911>3.0.CO;2-Q

Cite this

@article{de342ed207a74d1f82dab99303a58a06,

title = "An evaluation of recombinant leukocyte a interferon with aspirin in patients with metastatic renal cell cancer",

abstract = "The authors designed a clinical trial to assess the impact of aspirin (ASA) (600 mg four times daily) on the constitutional sequelae of recombinant leakocyte A interferon (IFN‐α2A), 20 × 106 U/m2 thrice weekly, in 29 patients with advanced renal cell cancer (RCC). Aspirin provided no meaningful amelioration of side effects compared to our prior experience of IFN‐α2A alone. Interestingly, the objective response rate of 34% (10/29) was considerably higher than the 15% recently reported from an aggregate of 344 patients participating in 14 prospective clinical trials. In light of small numbers, subtle selection biases, and the well‐recognized hazards of retrospective analyses, currently it is unclear if the apparent therapeutic advantage from ASA plus IFN‐α2A reflects chance occurrence or therapeutic potentiation from ASA. A randomized trial is planned to determine if ASA may have enhanced the efficacy of IFN‐α2A in patients with advanced RCC.",

author = "Creagan, {Edward T.} and Buckner, {Jan C.} and Hahn, {Richard G.} and Richardson, {Ronald R.} and Schaid, {Daniel J.} and Kovach, {John S.}",

year = "1988",

month = may,

day = "1",

doi = "10.1002/1097-0142(19880501)61:9<1787::AID-CNCR2820610911>3.0.CO;2-Q",

language = "English (US)",

volume = "61",

pages = "1787--1791",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "9",

}

TY - JOUR

T1 - An evaluation of recombinant leukocyte a interferon with aspirin in patients with metastatic renal cell cancer

AU - Creagan, Edward T.

AU - Buckner, Jan C.

AU - Hahn, Richard G.

AU - Richardson, Ronald R.

AU - Schaid, Daniel J.

AU - Kovach, John S.

PY - 1988/5/1

Y1 - 1988/5/1

N2 - The authors designed a clinical trial to assess the impact of aspirin (ASA) (600 mg four times daily) on the constitutional sequelae of recombinant leakocyte A interferon (IFN‐α2A), 20 × 106 U/m2 thrice weekly, in 29 patients with advanced renal cell cancer (RCC). Aspirin provided no meaningful amelioration of side effects compared to our prior experience of IFN‐α2A alone. Interestingly, the objective response rate of 34% (10/29) was considerably higher than the 15% recently reported from an aggregate of 344 patients participating in 14 prospective clinical trials. In light of small numbers, subtle selection biases, and the well‐recognized hazards of retrospective analyses, currently it is unclear if the apparent therapeutic advantage from ASA plus IFN‐α2A reflects chance occurrence or therapeutic potentiation from ASA. A randomized trial is planned to determine if ASA may have enhanced the efficacy of IFN‐α2A in patients with advanced RCC.

AB - The authors designed a clinical trial to assess the impact of aspirin (ASA) (600 mg four times daily) on the constitutional sequelae of recombinant leakocyte A interferon (IFN‐α2A), 20 × 106 U/m2 thrice weekly, in 29 patients with advanced renal cell cancer (RCC). Aspirin provided no meaningful amelioration of side effects compared to our prior experience of IFN‐α2A alone. Interestingly, the objective response rate of 34% (10/29) was considerably higher than the 15% recently reported from an aggregate of 344 patients participating in 14 prospective clinical trials. In light of small numbers, subtle selection biases, and the well‐recognized hazards of retrospective analyses, currently it is unclear if the apparent therapeutic advantage from ASA plus IFN‐α2A reflects chance occurrence or therapeutic potentiation from ASA. A randomized trial is planned to determine if ASA may have enhanced the efficacy of IFN‐α2A in patients with advanced RCC.

UR - http://www.scopus.com/inward/record.url?scp=0023906447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023906447&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19880501)61:9<1787::AID-CNCR2820610911>3.0.CO;2-Q

DO - 10.1002/1097-0142(19880501)61:9<1787::AID-CNCR2820610911>3.0.CO;2-Q

M3 - Article

C2 - 3162699

AN - SCOPUS:0023906447

SN - 0008-543X

VL - 61

SP - 1787

EP - 1791

JO - Cancer

JF - Cancer

IS - 9

ER -

An evaluation of recombinant leukocyte a interferon with aspirin in patients with metastatic renal cell cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this